Abstract:Rationale: Cardiac amyloidosis, considered for the last years to be a rare disease, is one of the determinants of HFpEF. The non-specific clinical presentation and the difficulties related to endomyocardial biopsy have made cardiac amyloidosis an underdiagnosed clinical entity. Improvement of non-invasive diagnostic techniques and the development of new therapies increased clinical awareness for this form of restrictive cardiomyopathy. We here summarize echocardiography and Tc-HDP scintigraphy findings in 6 cases of cardiac amyloidosis and review the literature data of this progressive and fatal cardiomyopathy. Patients concerns: The main clinical manifestations were fatigue, low exercise tolerance and edemas. The right heart failure symptoms usually dominated the clinical picture. Diagnoses: All cases were evaluated by echocardiography; 3 cases were further examined by bone scintigraphy and 4 cases a peripheral biopsy was performed. Electrocardiography showed low-voltage QRS complexes and "pseudo-infarct" pattern in the precordial leads, contrary to the echocardiographic aspect, which revealed thickening of ventricle walls. Biatrial dilation and diastolic disfunction were observed. Impaired systolic function was detected in advanced stages of the disease. Tc-HDP scintigraphy revealed cardiac uptake of radiopharmaceutical and managed to confirm the diagnosis in 1 case of cardiac amyloidosis in which salivary gland biopsy was negative. Interventions: The treatment was based on managing fluid balance, with the mainstream therapy represented by diuretics. Neurohormonal agents, usually used in heart failure treatment were avoided, due to poor tolerance and worsening of disease course. The management of these 6 cases was challenging due to the refractory manifestation of congestive heart failure. Outcomes: During follow-up, 4 of the 6 patients from the current study died in the first year after the final diagnosis was established. Lessons: Nuclear imaging of cardiac amyloidosis has a revolutionary development nowadays. Bone scintigraphy presents promising results for identifying patients at early stages of disease and to differentiate between cardiac amyloidosis types. Further studies are necessary for the standardization of imaging protocol and development of non-invasive diagnostic tools, especially in assessing the response to treatment and disease progression, for which little is known.

Amyloidosis in Heart Failure

Wild-Type Transthyretin Amyloidosis: A Prevalent and Underdiagnosed Cause of Heart Failure With Preserved Ejection Fraction

State of the Art of Cardiac Amyloidosis

Cardiac Amyloidosis As a Rare Cause of Heart Failure

Cardiac Amyloidosis: State-of-the-Art Review in Molecular Pathology

Opportunities for Earlier Diagnosis and Treatment of Cardiac Amyloidosis

Arrhythmic Manifestations of Cardiac Amyloidosis: Challenges in Risk Stratification and Clinical Management

Cardiac amyloidosis at a glance

Cardiac Amyloidosis: Evolving Pathogenesis, Multimodal Diagnostics, and Principles of Treatment.

Novel Insights into Non-Invasive Diagnostic Techniques for Cardiac Amyloidosis: A Critical Review

The role of echocardiography and 99mTc-HDP scintigraphy in non-invasive diagnosis of cardiac amyloidosis: A case series and literature review

Advances in the Diagnosis and Management of Cardiac Amyloidosis: A Literature Review

Advancements and challenges in cardiac amyloidosis imaging: A comprehensive review of novel techniques and clinical applications

[Clinical case of generalized amyloidosis (ATTR-amyloidosis) with a progressive course of chronic heart failure. Case report]

Histopathological and Immunohistochemical Characteristics of Different Types of Cardiac Amyloidosis

Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness

Diagnostic and therapeutic challenges in rapidly progressing cardiac amyloidosis: a literature review based on case report

Therapy of ATTR Cardiac Amyloidosis: Current Indications

Cardiovascular Magnetic Resonance Imaging for Amyloidosis: the State-of-the-art

Valvular heart disease in patients with cardiac amyloidosis

Breakthrough advances enhancing care in ATTR amyloid cardiomyopathy